Summary

Transcatheter aortic valve replacement (TAVR) has become a treatment option for patients with severe aortic stenosis who either are not surgical candidates or are at high risk for surgical complications. The results from the US CoreValve pivotal trials support the safety and efficacy of the CoreValve prosthesis in these patient populations. This article discusses detailed data from the CoreValve trials